Trials / Unknown
UnknownNCT03591666
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
A Non-randomized Phase II Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, phase II, open label study of anlotinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib p.o. qd |
Timeline
- Start date
- 2018-07-15
- Primary completion
- 2019-12-31
- Completion
- 2020-12-31
- First posted
- 2018-07-19
- Last updated
- 2018-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03591666. Inclusion in this directory is not an endorsement.